The discussions at this meeting will include forward-looking statements. Actual results could differ materially from those projected in the forward-looking statements. The factors that could cause actual results to differ are discussed in our 2007 Annual Report on Form 10-K and in our reports on Form 10-Q and 8-K. These reports are available on our website at www.pfizer.com in the “Investors – SEC Filings” section.
R&D Five Point Plan

- Aggressively Deliver the Phase 2 and Phase 3 Portfolio
- Prioritize Our Portfolio to Deliver the Most Value
- Become a Top-Tier Biotherapeutics Company
- Dramatically Raise the Bar on Productivity
- Pursue the Best External Science
85 distinct new molecular entities in our pipeline
- 26 biological programs in preclinical/clinical development

Pipeline breadth and depth in 10 therapeutic areas

Aggressive goal to rebuild our Phase 3 portfolio
- Total of 15 - 20 Phase 3 starts 2008 - 2009
- Phase 3 total programs grow to 24 - 28 by December 2009
- 15 - 20 regulatory submissions between 2010 - 2012
Pfizer R&D Pipeline
(as of February 28, 2008)

- Over 300 Discovery Projects

- **Accelerating Pipeline with Sharpened Focus on Key Disease Areas**

- **Strong flow of medicines expected to progress from Phase 2 to Phase 3**

- Approved Selzentry Lyrica Fibromyalgia fesoterodine (EU)
Today’s Phase 3 Portfolio

NMEs
- axitinib – Pancreatic Cancer
- tremelimumab – Melanoma
- apixaban – VTE Prevention
- CP-945598 – Obesity
- PD-332334 – GAD
- S,S-reboxetine – Fibromyalgia
- Zithromax/chloroquine – Malaria

New Indications
- apixaban – Atrial Fibrillation
- Sutent® capsules (sunitinib malate)
- Geodon® (ziprasidone HCl)
- Lyrica® capsules
- Eraxis® (anidulafungin IV)
- IV Oral Fend® (voriconazole)
- Selzentry® (maraviroc) tablets
Potential New Indications Expected To Drive Value

- Renal Cell Carcinoma & Gastrointestinal Stromal Tumor
- Breast
- Hepatocellular Carcinoma
- Non Small Cell Lung
- Colorectal

Revenues over Time
axitinib: Potential New Phase 3 Indications

- Ongoing Phase 3 trial in pancreatic cancer
- Anticipate at ASCO
  - Additional information on both pancreas and renal cell trials
- Expect two new Phase 3 starts:
  - Renal cell cancer
  - Non-small cell lung cancer

![Graph showing survival probability and hazard ratio for axitinib+gemcitabine and gemcitabine alone in pancreatic cancer.](image)

Study 1016
ECOG PS 0/1

<table>
<thead>
<tr>
<th>Survival Probability</th>
<th>Time (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>20</td>
</tr>
<tr>
<td>0.8</td>
<td>18</td>
</tr>
<tr>
<td>0.6</td>
<td>16</td>
</tr>
<tr>
<td>0.4</td>
<td>14</td>
</tr>
<tr>
<td>0.2</td>
<td>12</td>
</tr>
<tr>
<td>0.0</td>
<td>10</td>
</tr>
<tr>
<td>0.2</td>
<td>8</td>
</tr>
<tr>
<td>0.4</td>
<td>6</td>
</tr>
<tr>
<td>0.6</td>
<td>4</td>
</tr>
<tr>
<td>0.8</td>
<td>2</td>
</tr>
<tr>
<td>1.0</td>
<td>0</td>
</tr>
</tbody>
</table>

Hazard ratio = 0.683 (95% CI: 0.42, 1.11)
Median: 7.2 mo (95% CI: 6.0, 12.5)
Median: 5.7 mo (95% CI: 4.1, 8.8)

Spano J et al., ECCO 2007
### NMEs
- PF-3187207 – Glaucoma
- CP-751871 – Lung Cancer
- PF-4383119 – OA Pain
- PD-200390 – Insomnia
- PF-885706 – GERD
- PF-299804 – Cancer
- PH-797804 – RA
- IV sulopenem/Oral sulopenem pro-drug – Bacterial Infections
- PF-868554 – HCV
- PF-4194471 – HIV
- CP-690550 – RA
- PF-734200 – Diabetes
- PF-4522625 – Seasonal Flu
- UK-453061 – HIV

### New Indications
- apixaban – VTE treatment & ACS
- axitinib – RCC & Lung
- PF-4383119 – Chronic Pain
- tremelimumab – CRC
- S,S-reboxetine – DPN

**Projected 15–20 Phase 3 Starts 2008–2009**
CP-751871 (IGF-1R Ab): Proof Of Concept Established In 1st Line NSCLC

Study Design

Treatment-naïve Stage IIIB/IV NSCLC patients

Carboplatin/Paclitaxel (SOC)

Carboplatin/Paclitaxel + CP-751

Highly specific fully human antibody

Well tolerated – high potential to combine

Broad proof-of-concept development plan underway

Phase 2 Tumor Shrinkage Needs to Translate to Phase 3 Survival Benefit for Registration

* carboplatin/paclitaxel
Karp et al ASCO 2007; Karp et al IASLC 2007
CP-690550: JAK-3 Inhibitor

RA Phase 2a Response Rate

Phase 2b dose ranging in rheumatoid arthritis ongoing – anticipate presentation at ACR 2008

Simultaneous Development Programs in Psoriasis, Asthma, Transplant Rejection, Rheumatoid Arthritis and Crohn’s Disease

Kremer JM et al, ACR 2006
PF-4383119 (RN-624): Nerve Growth Factor Inhibitor

Projected 1st Biotherapeutic for Pain

- Blocks Nerve Growth Factor (NGF)
  - Humanized monoclonal antibody
- Efficacy demonstrated in Phase 2 osteoarthritis (OA) pain study
- Favorable safety profile to date
  - >600 patients treated
Panel 1
Baseline Pain = 43–46 mm
- Placebo
- 0.1 mg/kg
- 0.3 mg/kg
- 1.0 mg/kg

Panel 2
Baseline Pain = 54–60 mm
- Placebo
- 0.1 mg/kg
- 0.3 mg/kg
- 1.0 mg/kg

* p<0.05 vs placebo

NMEs
- axitinib – Pancreatic Cancer
- S,S-reboxetine – Fibromyalgia
- CP-945598 – Obesity
- PD-332334 – GAD
- IV sulopenem / Oral sulopenem pro-drug – Bacterial Infections
- UK-453061 – HIV
- Zithromax/chloroquine – Malaria
- PF-299804 – Cancer
- PF-885706 – GERD
- PF-4522625 – Seasonal Flu
- PH-797804 – RA
- PF-868554 – HCV
- PF-4194471 – HIV
- PF-734200 – Diabetes
- PD-200390 – Insomnia
- CP-751871 – 3rd Line NSCLC
- PF-4383119 – OA Pain
- CP-690550 – RA

New Indications
- axitinib – 1st Line NSCLC & 2nd Line RCC
- apixaban – VTE Treatment, AF & Acute Coronary Syndrome
- S,S-reboxetine – DPN
- CP-690550 – Psoriasis
- PF-4383119 – Chronic Pain
86 Biotherapeutics In The Pipeline

**Research**
- 60

**Development**
- 26

**Marketed**
- 5

**Diverse Portfolio**
- 8 TAs
- 6 Modalities
- 53 MAbs
- 8 Vaccines

**$1.4 B 2007 Revenues**
- Rebif® (interferon beta-1a)
- Fragmin® (dalteparin sodium injection)
- Genotropin®
- Somavert® (pegvisomant for injection)
- Macugen® (pegaptanib sodium injection)
<table>
<thead>
<tr>
<th>Category</th>
<th>Products &amp; Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved for HIV</td>
<td>Selzentry/Celsentri, Champix, Revatio, Spiriva Respimat, Xalacom, Fablyn</td>
</tr>
<tr>
<td>Approved for Smoking Cessation, PAH</td>
<td>Champix, Revatio, Spiriva Respimat, Xalacom, Fablyn</td>
</tr>
<tr>
<td>Submitted for COPD</td>
<td>Selzentry/Celsentri, Champix, Revatio, Spiriva Respimat, Xalacom, Fablyn</td>
</tr>
<tr>
<td>Submitted for Osteoporosis</td>
<td>Selzentry/Celsentri, Champix, Revatio, Spiriva Respimat, Xalacom, Fablyn</td>
</tr>
<tr>
<td>Submitted for Glaucoma (Japan)</td>
<td>Selzentry/Celsentri, Champix, Revatio, Spiriva Respimat, Xalacom, Fablyn</td>
</tr>
<tr>
<td>Advanced to Phase 3</td>
<td>PD-332334, S,S-reboxetine, Eraxis/Vfend, Geodon Adj Depression, axitinib &amp; Neurontin Peds (Japan)</td>
</tr>
<tr>
<td>Potential New Oncology Indications</td>
<td>Sutent, axitinib and tremelimumumab</td>
</tr>
<tr>
<td>Business Development</td>
<td>Encysive, CovX, Serenex, Coley</td>
</tr>
<tr>
<td>Early Portfolio</td>
<td>3 POCs, 11 FIPs, 17 FIHs</td>
</tr>
</tbody>
</table>
### Strong And Growing Portfolio

<table>
<thead>
<tr>
<th>New</th>
<th>In-Line</th>
<th>Established</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHANTIX</strong> (varenicline) tablets</td>
<td><strong>GEODON</strong> (Ziprasidone HCl)</td>
<td><strong>NORVASC</strong> (Amlodipine besylate)</td>
</tr>
<tr>
<td><strong>LYRICA</strong> (Pregabalin)</td>
<td><strong>CELEBREX</strong> (Celecoxib) capsules</td>
<td><strong>Cabaser</strong> (Naltrexone)</td>
</tr>
<tr>
<td><strong>Sutent</strong> (sunitinib malate)</td>
<td><strong>Viagra</strong> (Sildenafil citrate)</td>
<td><strong>Zoloft</strong> (Sertraline HCl)</td>
</tr>
<tr>
<td><strong>Selzentry</strong> (Maraviroc) tablets</td>
<td><strong>xalatan</strong> (Latanoprost)</td>
<td><strong>FRAGMIN</strong> (Eptifibatide)</td>
</tr>
<tr>
<td><strong>SOMAVERT</strong> (Pegvisomant)</td>
<td><strong>ABREXТАН</strong> (Donepezil)</td>
<td><strong>Diabetes HCl Tablets</strong></td>
</tr>
<tr>
<td><strong>Eraxis</strong> (Anidulafungin IV)</td>
<td><strong>Rebif</strong> (Interferon beta-1a)</td>
<td><strong>Diabetes HCl Tablets</strong></td>
</tr>
<tr>
<td><strong>Caduet</strong> (abiraterone acetate/azaxedistin calcium)</td>
<td><strong>Zyvox</strong> (Linezolid)</td>
<td><strong>Camptosar</strong> (Irinotecan)</td>
</tr>
<tr>
<td><strong>Aromasin Exemestane Tablets</strong></td>
<td><strong>Handihaler</strong> (Ipratropium)</td>
<td><strong>Accupril</strong> (Quinapril)</td>
</tr>
<tr>
<td><strong>Vfend (Voriconazole)</strong></td>
<td><strong>Viracept (Nelfinavir) Moxylate</strong></td>
<td><strong>Fluon (Fluconazole 150-mg tablet)</strong></td>
</tr>
<tr>
<td><strong>Genotropin</strong> (Recombinant)</td>
<td><strong>Zmax</strong> (Azithromycin)</td>
<td><strong>Depo-subQ provera 104</strong></td>
</tr>
<tr>
<td><strong>Aromasin</strong> (Exemestane)</td>
<td><strong>INSPIRIS eplerenone</strong></td>
<td><strong>Fluconazole 150-mg tablet</strong></td>
</tr>
</tbody>
</table>

**Dynastat** (Pramoxine Hydrochloride)